--- title: "GSK: Japan's MHLW Expands Eligible Population For Arexvy" type: "News" locale: "en" url: "https://longbridge.com/en/news/286723820.md" description: "GSK plc announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for its RSV vaccine, Arexvy, to include adults aged 18 to 49 at increased risk for RSV disease. This follows previous approvals for older adults. The decision was supported by Phase IIIb trial data showing a comparable immune response in the younger age group. GSK shares closed at 1,859.50 pence, down 0.16%." datetime: "2026-05-18T06:27:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286723820.md) - [en](https://longbridge.com/en/news/286723820.md) - [zh-HK](https://longbridge.com/zh-HK/news/286723820.md) --- # GSK: Japan's MHLW Expands Eligible Population For Arexvy Add as your preferred news source on Google Add Now GSK plc (GSK,GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include adults aged 18 to 49 years at increased risk for RSV disease. GSK's RSV vaccine was previously approved in Japan for the prevention of RSV disease in all adults aged 60 years and older, and for adults aged 50-59 AIR for RSV disease. The company said the approval was supported by data from a Phase IIIb trial demonstrating a non-inferior immune response in adults aged 18 to 49 years AIR for RSV disease compared to adults aged 60 years and above. The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed from Antigenics, a subsidiary of Agenus Inc. At last close, GSK plc shares were trading at 1,859.50 pence, down 0.16%. For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md) - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [AGEN.US](https://longbridge.com/en/quote/AGEN.US.md) - [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md) - [00847G804.US](https://longbridge.com/en/quote/00847G804.US.md) ## Related News & Research - [Pfizer’s New Japan RSV Vaccine Trial Signals Ongoing Expansion for PFE](https://longbridge.com/en/news/286445564.md) - [GSK China Hepatitis B Push Raises Questions For Valuation And Dividend Risks](https://longbridge.com/en/news/285980824.md) - [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md) - [](https://longbridge.com/en/news/285955820.md) - [Fact Check: Le vaccin contre la COVID-19 de Pfizer n'est pas connu pour déclencher une infection à hantavirus](https://longbridge.com/en/news/286224755.md)